Rezonic gets complete response

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it received a complete response letter from FDA for an NDA for Rezonic casopitant to prevent chemotherapy-induced nausea and vomiting (CINV) and postoperat...